Skip to main content

Krishnan Suma's Form 4 filing

Krystal Biotech, Inc. (KRYS) · filed Jan 5, 2023

Accession no.
0001298711-23-000004
Filed
Jan 5, 2023
Trade date
Jan 4, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market sales total $615.5K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Krishnan SumaCIK 0001298711Director, Officer (President, R&D), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 4, 2023Common StockSSaleDisposed−3,938$80.09F2−$315,394.421,702,263DirectDuplicate filing
Jan 4, 2023Common StockSSaleDisposed−3,748$80.08F2−$300,139.841,763,688IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The transaction was executed in multiple trades ranging from $80.0000 to $80.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)